Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, we identified two novel polymorphisms in the PSA promoter ARE2 region in breast cancer.
|
11299734 |
2001 |
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era.
|
18646000 |
2008 |
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that the presence of the A-AA allele at the PSA promoter region is associated with less aggressive forms of breast cancer and could be looked on as a favorable prognostic factor.
|
12168876 |
2002 |
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There was no significant association between the PSA gene polymorphism and breast cancer risk, nor was there significant gene-gene interaction.
|
16365023 |
2005 |
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Breast cancer prognostic significance of a single nucleotide polymorphism in the proximal androgen response element of the prostate specific antigen gene promoter.
|
10942096 |
2000 |
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Retrospective inception cohort study of male Veterans aged 40 to 89 years with a laboratory-defined low testosterone measurement from 2002 to 2011 and recent prostate specific antigen (PSA) testing; excluding those with recent testosterone treatment, prostate or breast cancer, high PSA or prior prostate biopsy.
|
29933385 |
2018 |
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Differences were detected in the completion of screening tests for colorectal cancer (p < 0.001), breast cancer (p = 0.023), cervical cancer (p = 0.006), and prostate-specific antigen determination (p < 0.001) in relation to the participants' academic profiles.
|
31848937 |
2019 |
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Current smoking (RR=0.86, 0.83-0.90), non-participation in breast cancer screening (female) or PSA testing (male) (RR=0.84, 0.81-0.86), poor self-reported health (RR=0.89, 0.86-0.91), lower levels of education (RR=0.91, 0.90-0.93), and not speaking English at home (RR=0.88, 0.85-0.91) were associated with reduced ever-uptake of screening within the NBCSP and of any CRC screening.
|
29109015 |
2018 |
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Previous studies have shown that the coding region of the PSA gene is not a target for mutations in prostate cancer and breast cancer.
|
11185746 |
2000 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
One of these genes encodes for prostate-specific antigen (PSA), a favorable prognostic factor in breast cancer.
|
10794483 |
2000 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the additive value of the prostate cancer gene 3 (PCA3) urine test to serum prostate-specific antigen (PSA) in prostate cancer (PC) screening among breast cancer, early-onset gene (BRCA) mutation carriers.
|
25746941 |
2015 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
We were able to detect the amplified PSA fragment in 18 of 78 women with breast cancer; 7 of the 18 women with the PSA fragment had localised, small, node-negative tumours, both oestrogen receptor (ER) positive and ER negative.
|
8826851 |
1996 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Survival analysis showed that patients with PSA-producing tumors have a reduced risk for relapse, suggesting PSA to be an independent favorable prognostic marker for a large subset of breast cancer patients.
|
9541191 |
1998 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The substantial decrease in breast cancer mortality in women below regular screening age and the reductions in mortality from both cancers in Denmark from the mid-1990s are consistent with beneficial contributions from improved treatment besides mammography screening and increased PSA testing.
|
28795403 |
2017 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Like the genes that encode PSA and other kallikreins, the KLK5 gene was found to be regulated by steroid hormones in the BT-474 breast cancer cell line.
|
12142380 |
2002 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
We screened 13 well-characterized breast cancer cell lines for hK2 and PSA production upon <i>in vitro</i> hormone stimulation by testosterone [dihydrotestosterone (DHT)].
|
30254080 |
2019 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum PSA could be a useful biomarker for the diagnosis of breast cancer, and a biomarker for the differential diagnosis of breast cancer from benign breast tumors.
|
30024607 |
2018 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
A pilot study was performed using both EST and SAGE vNorthern to analyze the expression of a panel of known genes, including high abundance genes beta-actin and G3PDH, low abundance genes BRCA1 and p53, tissue-specific genes CEA and PSA and two breast cancer-related genes Her2/neu and MUC1.
|
15647832 |
2005 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate specific antigen has recently been shown to be an independent favourable prognostic marker for breast cancer.
|
12439720 |
2002 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical significance of serum PSA in breast cancer patients.
|
31664946 |
2019 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Like KLK2 and KLK3, the KLK5 gene is regulated by steroid hormones in the BT-474 breast cancer cell line.
|
11948967 |
2002 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Use of CRC screening tests was significantly lower than mammography for breast cancer detection in women (20 vs. 82%, P<0.001) and use of serum prostate-specific antigen for prostate cancer detection in men (27 vs. 46%, P<0.001).
|
21989122 |
2011 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
( n = 73); 2) Angina: treatment options ( n = 88); 3) Breast cancer: surgical options ( n = 265); 4) Prostate Specific Antigen (PSA) test: yes or no?
|
29078054 |
2018 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
To account for unmeasured factors, the correlation between changes in PSA screening over time and changes in screening for colorectal and breast cancer were assessed.All analyses were conducted in 2016.
|
29056579 |
2018 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
As IGFs, IGFBPs and PSA are all present in breast cancer, possible associations among these proteins were speculated.
|
8883411 |
1996 |